[HT-09] Hot Topics 09
Is the concept of embolic stroke of undertermined source (ESUS) dead or alive?

[HT-09-3] Decision making of patent foramen ovale closure by brain and heart team

^○Hiroshi Yamagami (Department of Stroke Neurology, National Hospital Organization Osaka National Hospital, Japan)

Two clinical trials to compare direct oral anticoagulants (DOACs) and aspirin did not show superiority of DOACs over aspirin in patients with embolic stroke of undertermined source (ESUS). It is argued on the reasons for the negative results that covert atrial fibrilltion may not be a major cause and arteriogenic embolism may be prevalent than ever thought. In this symposium, we analyze the factors affecting the results, reconsider the the currrent concept of EUS, and perspect future direction of antithrombotic therapy.

1997 ~ 2000 Resident, Cerebrovascular Division, Department of Medicine, National Cerebral and Cardiovascular Center
2000 ~ 2004 Graduate School of Medicine, Osaka University
2005 ~ 2012 Department of Neurology, Stroke Center, Kobe City Medical Center General Hospital
2012 ~ 2019 Chief, Department of Neurology and Division of Stroke Care Unit, National Cerebral and Cardiovascular Center
2019 ~ present Director, Department of Stroke Neurology, National Hospital Organization Osaka National Hospital

Board Certified Member of the Japanese Society of Internal Medicine, the Japan Stroke Society, and Japanese Society for Neuroendovascular Therapy
Director of the Japanese Society for Neuroendovascular Therapy and the Japan Academy of Neurosonology.
Delegate of the Japanese Society of Neurology, the Japan Stroke Society, and the Japan Society of Embolus Detection and Treatment.